Four cardiac hormones eliminate up to two-thirds of human breast cancers in athymic mice

In Vivo

Volumn 21, Issue 6, 2007, Pages 973-978

  Vesely, David L ^a,b   Vesely, Brian A ^a   Eichelbaum, Ehrentraud J ^a   Sun, Ying ^a   Alli, Abdel A ^a   Gower Jr , William R ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Breast cancer; Metastasis; Natriuretic peptides; New therapeutics; Receptors

Indexed keywords

ANTINEOPLASTIC AGENT; ATRIAL NATRIURETIC FACTOR; HORMONE RECEPTOR; KALIURETIC PEPTIDE; LONG ACTING NATRIURETIC PEPTIDE; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR C; UNCLASSIFIED DRUG; VESSEL DILATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; TREATMENT DURATION;

EID: 37349091248     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Jemel A, Siegel R, Murray T, Xu J and Thun MJ: Cancer Statistics, 2007. CA Cancer J Clin 55: 43-66, 2007.
2. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
3. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Solivan SR, Gower WR Jr and Vesely DL: Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest 35: 60-69, 2005.
4. Brenner BM, Ballermann BJ, Gunning ME and Zeidel ML: Diverse biological actions of atrial natriuretic peptide. Physiol Rrev 70: 665-699, 1990.
5. Vesely DL: Natriuretic peptides and acute renal failure. Am J Physiol 285: 17167-17177, 2003.
6. Vesely DL: Natriuretic hormones. In: The Kidney: Physiology and Pathophysiology, 4th edition. Alpern RJ and Herbert SC (eds.). Elsevier Inc, pp. 947-977, 2007.
7. Vesely DL: Atrial natriuretic peptide prohormone gene expression: Hormones and diseases that upregulate its expression. IUBMB Life 53: 153-159, 2002.
8. Ahmadian M, Wistuba II, Fong KM, Behrens C, Kodagoda DR, Saboorian MH, Shay J, Tomlinson GE, Blum J, Minna JD and Gazdar AF: Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res 57: 3664-3668, 1977.
9. Pathak S, Siciliano MJ, Cailleau R, Wiseman CL and Hsu TC: A human breast adenocarcinoma with chromosome and isoenzyme markers similar to those of the HeLa line. J Natl Cancer Inst 62: 263-271, 1979.
10. Duguay D, Mercier F, Stagg J, Martineau D, Bramson J, Servant M, Lin R, Galipeau J and Hiscott J: In vivo interferon regulatory factor 3-tumor suppressor activity in B16 melanoma tumors. Cancer Res 62: 5148-5152, 2002.
11. Vesely BA, Alli AA, Song S, Gower WR Jr, Sanchez-Ramos J and Vesely DL: Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest 35: 700-710, 2005.
12. Gower WR Jr, Vesely BA, Alli AA and Vesely DL: Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via guanosine 3′5′-cyclic monophosphate. Int J Gastrointest Cancer 36: 77-88, 2005.
13. Vesely DL, Cornett LE, McCleod SL, Nash AA and Norris JS: Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67, and 99-126. Peptides 11: 193-197, 1990.
14. Vesely DL, Arnold WC, Winters CJ, Sallman AL and Rico DM: Increased circulating concentration of the N-terminus of the atrial natriuretic prohormone in persons with pheochromocytomas. J Clin Endocrinol Metab 71: 1138-1146, 1990.
15. Vesely DL, Sallman AL and Bayliss JM: Specific binding sites for pro atrial natriuretic factors 1-30, 31-67, and 99-126 on distal nephrons, proximal tubules, renal cortical and medullary membranes. Renal Physiol Biochem 15: 23-32, 1992.
16. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells. Anticancer Res 26: 3217-3222, 2006.
17. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells. Anticancer Res 26: 4143-4418, 2006.
18. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 27: 1387-1392, 2007.
19. Sun Y, Eichelbaum DJ, Wang H and Vesely DL: Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 27: 3813-3818, 2007.
20. Saba SR, Garces AH, Clark LC, Soto J, Gower WR Jr and Vesely DL: Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long acting natriuretic peptide, and kaliuretic peptide in human pancreatic adenocarcinomas. J Histochem Cytochem 53: 989-995, 2005.